Clinical Trials · NCT04287179
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Withdrawn
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 0
- Start date
- Mar 2020
- Locations
- 25 sites, 4 countries
- Primary endpoint
- Change in glycosylated haemoglobin (HbA1c)